Delix Therapeutics is a clinical-stage neuroscience company developing orally available, non-hallucinogenic neuroplastogen medicines intended to rapidly repair brain synapses and treat neuropsychiatric and neurological disorders.

Founders

• David E. Olson · Co-Founder, Chief Innovation Officer, Head of the SAB
  He studied chemistry and neuroscience at Stanford University and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, and his academic lab at the University of California, Davis discovered that psychedelics promote structural and functional neuroplasticity in the cortex.
• Nick Haft · Co-Founder, Delix and Managing Director at OMX Ventures
  Before OMX Ventures, he was the sole managing partner at Arcos Ventures, where he deployed more than $80 million into more than 20 bio-related companies, and he holds a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.